Curesponse

CuresponseCuresponse
Curesponse

Curesponse

Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.

Website
2017Active14
Rate
Advertise here

About

Curesponse is a personalized medicine company that provides a functional drug sensitivity testing platform to guide cancer treatment. Their technology aims to predict patient response to various therapies by testing drugs on live tumor samples, thereby improving treatment accuracy and patient outcomes.

Technology stack

detected 2026-07-01
Emailunknown
Hosting
Google Cloud
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does Curesponse do?

Curesponse is a personalized medicine company that provides a functional drug sensitivity testing platform to guide cancer treatment. Their technology aims to predict patient response to various therapies by testing drugs on live tumor samples, thereby improving treatment accuracy and patient outcomes.

How much funding has Curesponse raised?

Curesponse has raised a total of $28M in funding. The most recent round on record is Series B.

Where is Curesponse headquartered?

Curesponse is headquartered in Tel Aviv, Israel.

When was Curesponse founded?

Curesponse was founded in 2017.

What industry does Curesponse operate in?

Curesponse operates in Life Sciences, Cancer, Genomics, Genome Sequencing, HealthTech, MedTech.

How many employees does Curesponse have?

Curesponse has approximately 14 people on record.

What is Curesponse's revenue?

StartupHub estimates Curesponse's annual revenue at $2.5M (range $1.3M to $3.8M, 64% confidence), based on comparable companies in the sector.

What is Curesponse's valuation?

StartupHub estimates Curesponse's effective valuation at $114.8M (range $70.0M to $168.0M, 10% confidence), based on comparable companies in the sector.